Amy J Bregar1, Alexander Melamed2, Elisabeth Diver2, Joel T Clemmer2, Shitanshu Uppal3,4, John O Schorge2, Laurel W Rice5, Marcela G Del Carmen2, J Alejandro Rauh-Hain2. 1. Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. abregar@mgh.harvard.edu. 2. Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 3. Division of Gynecologic Oncology, University of Michigan, Ann Arbor, MI, USA. 4. Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA. 5. Division of Gynecologic Oncology, University of Wisconsin, Madison, WI, USA.
Abstract
PURPOSE: The aim of this study was to determine factors associated with the adoption of minimally invasive surgery (MIS) compared with laparotomy in the treatment of endometrial cancer and to compare surgical outcomes and survival between these two surgical modalities. METHODS: We utilized the National Cancer Data Base (NCDB) to identify women diagnosed with presumed early-stage endometrial cancer between 2010 and 2012. We also identified factors associated with the performance of MIS and utilized propensity score matching to create a matched cohort of women who underwent minimally invasive staging surgery or laparotomy for surgical staging. RESULTS: Overall, 20,346 women were eligible for inclusion in the study; 12,604 (61.9%) had MIS, while 7742 (38.1%) had a laparotomy. African American race (odds ratio [OR] 0.54, 95% confidence interval [CI] 0.49-0.60], Hispanic ethnicity (OR 0.70, 95% CI 0.61-0.80), Charlson score >2 (OR 0.79, 95% CI 0.69-0.91), high-grade histology (OR 0.63, 95% CI 0.59-0.68), presumed clinical stage II disease (OR 0.53, 95% CI 0.46-0.60), and surgery at a community cancer program (OR 0.46, 95% CI 0.39-0.55) or in the Midwest region (OR 0.70, 95% CI 0.64-0.76) were associated with a decreased likelihood of having MIS, while private insurance (OR 1.69, 95% CI 1.45-1.97) and highest quartile median household income (OR 1.13, 95% CI 1.03-1.24) were associated with an increased likelihood of having MIS. After propensity score matching, there was no association between minimally invasive staging surgery and 3-year overall survival (hazard ratio 1.03, 95% CI 0.92-1.16). CONCLUSION: There are notable racial, ethnic, socioeconomic, and geographic variations in the utilization of MIS for endometrial cancer staging in the US. After controlling for the aforementioned factors, MIS had a similar 3-year survival compared with laparotomy in women undergoing staging surgery for endometrial cancer.
PURPOSE: The aim of this study was to determine factors associated with the adoption of minimally invasive surgery (MIS) compared with laparotomy in the treatment of endometrial cancer and to compare surgical outcomes and survival between these two surgical modalities. METHODS: We utilized the National Cancer Data Base (NCDB) to identify women diagnosed with presumed early-stage endometrial cancer between 2010 and 2012. We also identified factors associated with the performance of MIS and utilized propensity score matching to create a matched cohort of women who underwent minimally invasive staging surgery or laparotomy for surgical staging. RESULTS: Overall, 20,346 women were eligible for inclusion in the study; 12,604 (61.9%) had MIS, while 7742 (38.1%) had a laparotomy. African American race (odds ratio [OR] 0.54, 95% confidence interval [CI] 0.49-0.60], Hispanic ethnicity (OR 0.70, 95% CI 0.61-0.80), Charlson score >2 (OR 0.79, 95% CI 0.69-0.91), high-grade histology (OR 0.63, 95% CI 0.59-0.68), presumed clinical stage II disease (OR 0.53, 95% CI 0.46-0.60), and surgery at a community cancer program (OR 0.46, 95% CI 0.39-0.55) or in the Midwest region (OR 0.70, 95% CI 0.64-0.76) were associated with a decreased likelihood of having MIS, while private insurance (OR 1.69, 95% CI 1.45-1.97) and highest quartile median household income (OR 1.13, 95% CI 1.03-1.24) were associated with an increased likelihood of having MIS. After propensity score matching, there was no association between minimally invasive staging surgery and 3-year overall survival (hazard ratio 1.03, 95% CI 0.92-1.16). CONCLUSION: There are notable racial, ethnic, socioeconomic, and geographic variations in the utilization of MIS for endometrial cancer staging in the US. After controlling for the aforementioned factors, MIS had a similar 3-year survival compared with laparotomy in women undergoing staging surgery for endometrial cancer.
Authors: Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu Journal: Virchows Arch Date: 2021-02 Impact factor: 4.064
Authors: Anastasia Jermihov; Liwei Chen; Maria F Echavarria; Emily P Ng; Frank O Velez; Carla C Moodie; Joseph R Garrett; Jacques P Fontaine; Eric M Toloza Journal: Cureus Date: 2022-06-22
Authors: Anthony T Nguyen; Michael Luu; Jon Mallen-St Clair; Alain C Mita; Kevin S Scher; Diana J Lu; Stephen L Shiao; Allen S Ho; Zachary S Zumsteg Journal: JAMA Oncol Date: 2020-10-01 Impact factor: 31.777
Authors: Alexander Melamed; Daniel J Margul; Ling Chen; Nancy L Keating; Marcela G Del Carmen; Junhua Yang; Brandon-Luke L Seagle; Amy Alexander; Emma L Barber; Laurel W Rice; Jason D Wright; Masha Kocherginsky; Shohreh Shahabi; J Alejandro Rauh-Hain Journal: N Engl J Med Date: 2018-10-31 Impact factor: 91.245
Authors: Thomas Papathemelis; Helen Oppermann; Stella Grafl; Michael Gerken; Armin Pauer; Sophia Scharl; Anton Scharl; Elisabeth Inwald; Atanas Ignatov; Olaf Ortmann; Monika Klinkhammer-Schalke; Alexander Hein; Matthias W Beckmann; Michael P Lux Journal: J Cancer Res Clin Oncol Date: 2020-01-04 Impact factor: 4.553
Authors: Whitney E Zahnd; Cathryn Murphy; Marie Knoll; Gabriel A Benavidez; Kelsey R Day; Radhika Ranganathan; Parthenia Luke; Anja Zgodic; Kewei Shi; Melinda A Merrell; Elizabeth L Crouch; Heather M Brandt; Jan M Eberth Journal: Int J Environ Res Public Health Date: 2021-02-03 Impact factor: 3.390
Authors: Kristin Bixel; David A Barrington; Monica H Vetter; Adrian A Suarez; Ashley S Felix Journal: J Minim Invasive Gynecol Date: 2021-08-01 Impact factor: 4.137